Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-{gamma}-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

Conclusions New onset psoriasiform skin lesions develop in nearly 5% of anti-TNF-treated patients with IBD. We identified smoking as a main risk factor for developing these lesions. Anti-TNF-induced psoriasiform skin lesions are characterised by Th17 and Th1 cell infiltrates. The number of IL-17A-expressing T cells correlates with the severity of skin lesions. Anti-IL-12/IL-23 antibody therapy is a highly effective therapy for these lesions.

http://gut.bmj.com/cgi/content/short/63/4/567?rss=1

Source: Gut - February 27, 2014 Category: Gastroenterology Authors: Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., Maier, H., Koburger, M., Wagner, J., Glas, J., Diegelmann, J., Koglin, S., Dombrowski, Y., Schauber, J., Wollenberg Tags: Crohn's disease Inflammatory bowel disease Source Type: research